ROR1 and leukemia: Cirmtuzumab has currently completed a phase I clinical trial in patients with relapsed or refractory CLL, in which treatment with cirmtuzimab inhibited leukemia-cell activation of Rho-GPTPase and ROR1 signaling [23].